Methotrexate—why it remains the anchor DMARD after 40 years
Rheumatoid arthritis treatment has changed dramatically, but the practical question in clinic has not: which medicine best controls inflammation, protects joints, and leaves room for safer escalation if needed? After four decades, methotrexate still answers that question more often than any other conventional synthetic disease-modifying antirheumatic drug, or csDMARD.
That durability matters. Patients want to know why an older drug is offered before biologic DMARDs or Janus kinase inhibitors. Referring clinicians want to know when “start methotrexate” reflects habit versus evidence. The short answer is that methotrexate remains the anchor because it combines proven efficacy, predictable monitoring, low cost, flexible dosing, and synergy with later therapies.
Evidence, not nostalgia
Current guidelines keep methotrexate at the center. The 2021 American College of Rheumatology rheumatoid arthritis guideline conditionally recommends methotrexate over hydroxychloroquine or sulfasalazine for patients with moderate to high disease activity, and over starting a biologic or targeted synthetic DMARD in most DMARD-naive patients. EULAR recommendations similarly place methotrexate, with short-term glucocorticoids when appropriate, as the first strategic step unless contraindications exist.
This is not because methotrexate works for everyone. It does not. It is because trials and registries repeatedly show that early methotrexate-based treat-to-target care can induce remission or low disease activity, reduce erosive damage, and identify quickly who needs escalation. Studies such as CAMERA and TICORA helped establish tight control: measure disease activity, adjust therapy, and avoid therapeutic drift.
What “anchor” means clinically
Anchor does not mean “only option.” It means the reference point. Methotrexate is often continued when a tumor necrosis factor inhibitor, abatacept, tocilizumab, rituximab, or a JAK inhibitor is added because combination therapy improves drug persistence and can reduce anti-drug antibody formation with several biologics.
Why the molecule still performs
Methotrexate’s anti-inflammatory effect in rheumatoid arthritis is not simply “chemotherapy at a lower dose.” Weekly low-dose methotrexate increases extracellular adenosine signaling, which dampens inflammatory cell activity and cytokine production. It also affects folate-dependent pathways, which is why folic acid supplementation reduces mouth sores, nausea, and liver enzyme abnormalities without usually sacrificing benefit.
Clinically, methotrexate has several advantages that newer drugs have not erased:
- oral or subcutaneous dosing, with subcutaneous use improving absorption at higher weekly doses
- a long safety record in renal, hepatic, pulmonary, infectious, and perioperative decision-making
- compatibility with many biologic DMARD strategies when monotherapy is not enough
- laboratory monitoring that detects most toxicity before it becomes clinically severe
Practical monitoring checklist
| Before or during therapy | Why it matters | What patients can ask |
|---|---|---|
| Baseline CBC, kidney function, and liver enzymes | Helps confirm methotrexate can be used and monitored safely | Are my baseline labs appropriate for methotrexate? |
| Folic acid plan | Can reduce mouth sores, nausea, and liver enzyme issues | How should I take folic acid with my weekly dose? |
| Alcohol, pregnancy, infection, and medication review | Identifies situations where methotrexate may need extra caution or avoidance | Are any of my medicines or plans unsafe with methotrexate? |
| Follow-up labs after starting or changing dose | Detects blood count, kidney, or liver changes early | When should my next monitoring labs be checked? |
| Treat-to-target reassessment | Determines whether symptoms and joint inflammation are improving enough | What is our target, and when would we escalate treatment? |
Consider a 46-year-old with new anti-CCP-positive rheumatoid arthritis, swollen wrists and metacarpophalangeal joints, morning stiffness, and a CDAI, or Clinical Disease Activity Index, in the high range. Starting methotrexate, titrating promptly, supplementing folic acid, and reassessing in 8 to 12 weeks creates a measurable experiment. If the CDAI falls meaningfully, the plan is working. If not, the baseline therapy is already in place for rational escalation.
The main misconception: older means less sophisticated
Age is a poor measure of therapeutic value. Prednisone is old and toxic when used chronically; methotrexate is old and often disease-modifying. The relevant questions are different: What outcome does it improve? How often? At what risk? Under what monitoring?
Another misconception is that side effects are random. In practice, risk is actively managed. Rheumatologists consider kidney function, liver disease, alcohol use, pregnancy plans, cytopenias, interstitial lung disease history, infection risk, drug interactions, and vaccination status. Baseline and follow-up complete blood counts, creatinine, and liver enzymes are not bureaucracy; they are part of why the drug can be used safely at scale.
Methotrexate is also not appropriate in pregnancy, and contraception counseling is part of responsible prescribing. Nausea, fatigue after the dose, mouth ulcers, elevated transaminases, and low blood counts deserve attention, but they usually lead to dose adjustments, folate changes, route changes, or discontinuation rather than alarm.
Where methotrexate fits in modern escalation
The strongest contemporary strategy is not “try methotrexate forever.” It is treat to target. Remission, or at least low disease activity, should be defined, measured, and pursued. If methotrexate at an effective dose is insufficient, adding or switching therapy is evidence-based, not a failure. Patients comparing arthritis patterns may also find the RA vs osteoarthritis guide helpful.
The ACR guideline emphasizes shared decision-making because the best next step depends on disease severity, serologies such as rheumatoid factor and anti-CCP, erosions, comorbidities, insurance realities, infection risk, and patient preferences. For some, triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine remains reasonable. For others, a biologic or targeted synthetic DMARD is the better next move.
What the evidence supports now
After 40 years, methotrexate remains the anchor DMARD, though newer tools are important. Evidence supports early use, adequate dosing, folic acid, monitoring, and timely escalation when targets are missed. Uncertainty remains in predicting response and intolerance. The open question is how to personalize what follows.